Given the early data showing high rates of response to combinations of an ICI and a VEGFR-targeted agent in patients with ccRCC, combinations are now being explored in clinical trials in non–ccRCC, including tRCC [NCT02724878, NCT02496208]. This evidence concerns the gene KDR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.